CVKD net incomeQ2 2026-$3.32M
CVKD net income was -$3.32M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.67M a year earlier. For the full fiscal 2025 it was -$13.24M, compared with -$10.65M in fiscal 2024.
Cadrenal Therapeutics Inc. (CVKD) financials
For the twelve months ended Jun 30, 2026, Cadrenal Therapeutics Inc. reported -$11.54M of net income.
- Net income, TTM
- -$11.54M
- EPS, diluted, TTM
- -$4.86
- Cash
- $2.39M
- Market cap
- $4.9M
FY2023FY2025
FY2023FY2025
CVKD revenue and earnings growth
CVKD EPSQ2 2026-$1.14
CVKD diluted EPS was -$1.14 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.64.
CVKD free cash flowQ4 2025-$2.57M
CVKD free cash flow was -$2.57M in fiscal Q4 2025 (ended Dec 31, 2025). For the full fiscal 2025 it was -$12.61M, compared with -$7.36M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cost of revenue | - | - | $220.1K |
| Research and development | $4.10M | $4.21M | $4.08M |
| Selling, general and admin | $9.35M | $6.75M | $3.55M |
| Operating income | -$13.46M | -$10.96M | -$7.63M |
| Interest expense | - | - | $3.5K |
| Net income | -$13.24M | -$10.65M | -$8.36M |
| EPS, basic | -$6.64 | -$8.73 | -$9.29 |
| EPS, diluted | -$6.64 | -$8.73 | -$9.29 |
| Diluted shares | 2.0M | 1.2M | 899,465 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $4.01M | $10.02M | $8.40M |
| Current assets | $4.32M | $10.11M | $8.49M |
| Total assets | $4.33M | $10.12M | $8.52M |
| Current liabilities | $1.59M | $2.68M | $826.9K |
| Total liabilities | $1.59M | $2.68M | $826.9K |
| Shareholders' equity | $2.74M | $7.44M | $7.69M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$12.60M | -$7.36M | -$3.53M |
| Capital expenditures | $5.1K | $6.5K | $3.3K |
| Free cash flow | -$12.61M | -$7.36M | -$3.53M |
| Investing cash flow | -$5.1K | -$6.5K | -$3.3K |
| Financing cash flow | $6.60M | $8.98M | $11.90M |
| Stock-based compensation | $1.94M | $1.42M | $710.4K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Research and development | $705.2K | $771.5K | $666.3K | $688.5K | $1.08M | $1.67M | $1.54M | $784.6K | $1.25M | $629.0K | $361.1K | $243.9K |
| Selling, general and admin | $2.63M | $1.74M | $2.40M | $2.04M | $2.66M | $2.25M | $2.74M | $1.67M | $1.21M | $1.13M | $902.1K | $898.1K |
| Operating income | -$3.34M | -$2.51M | -$3.07M | -$2.73M | -$3.73M | -$3.93M | -$4.28M | -$2.46M | -$2.47M | -$1.76M | -$1.26M | -$1.14M |
| Interest expense | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Net income | -$3.32M | -$2.50M | -$3.04M | -$2.69M | -$3.67M | -$3.85M | -$4.19M | -$2.41M | -$2.39M | -$1.66M | -$1.14M | -$1.04M |
| EPS, basic | -$1.14 | -$1.04 | -$1.37 | -$1.31 | -$1.87 | -$2.09 | -$2.75 | -$2.18 | -$2.24 | -$1.56 | - | -$1.01 |
| EPS, diluted | -$1.14 | -$1.04 | -$1.37 | -$1.31 | -$1.87 | -$2.09 | -$2.75 | -$2.18 | -$2.24 | -$1.56 | - | -$1.01 |
| Diluted shares | 2.9M | 2.4M | - | 2.0M | 2.0M | 1.8M | - | 1.1M | 1.1M | 1.1M | - | 1.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.39M | $2.31M | $4.01M | $3.86M | $5.57M | $7.34M | $10.02M | $4.36M | $5.04M | $6.57M | $8.40M | $9.11M |
| Current assets | $5.58M | $2.86M | $4.32M | $4.08M | $5.97M | $7.94M | $10.11M | $4.67M | $5.44M | $7.03M | $8.49M | $9.28M |
| Total assets | $5.59M | $2.86M | $4.33M | $4.09M | $5.98M | $7.95M | $10.12M | $4.68M | $5.46M | $7.05M | $8.52M | $9.31M |
| Current liabilities | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M | $1.27M | $1.46M | $856.3K | $826.9K | $563.6K |
| Total liabilities | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M | $1.27M | $1.46M | $856.3K | $826.9K | $565.8K |
| Shareholders' equity | $4.09M | $1.80M | $2.74M | $2.73M | $4.30M | $6.11M | $7.44M | $3.41M | $3.99M | $6.19M | $7.69M | $8.75M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.23M | -$3.00M | -$2.57M | -$2.36M | -$3.03M | -$4.65M | -$1.79M | -$2.20M | -$1.53M | -$1.84M | -$694.4K | -$627.8K |
| Capital expenditures | - | - | $0 | $1.9K | $0 | $3.3K | - | - | - | - | $0 | $1 |
| Free cash flow | - | - | -$2.57M | -$2.36M | -$3.03M | -$4.65M | - | - | - | - | -$694.4K | -$627.8K |
| Investing cash flow | - | - | $0 | -$1.9K | $0 | -$3.3K | - | - | - | - | $0 | -$1 |
| Financing cash flow | $2.31M | $1.30M | $2.72M | $648.4K | $1.26M | $1.97M | $7.45M | $1.53M | $0 | $298 | -$12.5K | $6.51M |
| Stock-based compensation | $672.1K | $252.4K | $325.1K | $473.4K | $592.6K | $548.8K | $763.2K | $300.0K | $193.1K | $162.7K | $103.1K | $153.1K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.73 | 2.68 | 2.72 | 3.02 | 3.56 | 4.32 | 3.77 | 3.69 | 3.72 | 8.21 | 10.27 | 16.46 |
Source: XBRL data Cadrenal Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Nov 7, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CVKD peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CVKD | - | - | -$11.54M | - | $4.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CVKD FAQ
5 questionsIs CVKD profitable?
No. Cadrenal Therapeutics Inc. reported a net loss of $11.54M for the twelve months ended Jun 30, 2026.How much cash and debt does CVKD have?
Cadrenal Therapeutics Inc. reported $2.39M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CVKD earnings per share?
Diluted earnings per share were -$4.86 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CVKD last report financial results?
The latest statements here come from Cadrenal Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this CVKD financial data come from?
Quantisnow builds these statements from the structured XBRL data Cadrenal Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.